Liquidia (NASDAQ:LQDA) Stock: Insider Sanjeev Khindri Sells 1,101 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Sanjeev Khindri sold 1,101 shares of the company’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $31,356.48. Following the completion of the transaction, the insider owned 64,846 shares of the company’s stock, valued at $1,846,814.08. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Up 26.6%

LQDA opened at $33.94 on Thursday. The business’s fifty day simple moving average is $62.30 and its 200 day simple moving average is $61.74. Liquidia Corporation has a 52 week low of $21.94 and a 52 week high of $93.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The stock has a market cap of $3.04 billion, a PE ratio of 24.77 and a beta of 0.61.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The firm had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter in the previous year, the business earned ($0.49) EPS. The company’s revenue for the quarter was up 1842.1% on a year-over-year basis. As a group, research analysts expect that Liquidia Corporation will post 2.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Liquidia

A number of large investors have recently added to or reduced their stakes in LQDA. Globeflex Capital L P bought a new stake in Liquidia in the second quarter worth $175,000. Nykredit A S purchased a new stake in Liquidia during the second quarter valued at about $177,000. Fluent Financial LLC purchased a new stake in Liquidia during the second quarter valued at about $287,000. WINTON GROUP Ltd bought a new position in shares of Liquidia during the second quarter valued at about $335,000. Finally, Fulcrum Equity Management bought a new position in shares of Liquidia during the second quarter valued at about $399,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analyst Ratings Changes

LQDA has been the topic of a number of research reports. Lifesci Capital raised Liquidia from a “market perform” rating to an “outperform” rating and set a $59.00 price objective on the stock in a report on Wednesday. HC Wainwright dropped their target price on Liquidia from $130.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, October 2nd. Wall Street Zen downgraded Liquidia from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Weiss Ratings raised Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. Finally, Raymond James Financial reaffirmed an “outperform” rating on shares of Liquidia in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Liquidia presently has an average rating of “Hold” and a consensus target price of $77.31.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: The settlement allows Liquidia to continue commercializing YUTREPIA for pulmonary arterial hypertension (PAH) without interruption, removing a major source of legal and commercial uncertainty. Liquidia settlement announcement
• Positive Sentiment: Preliminary third-quarter YUTREPIA sales reached $222.7 million, contributing to $396.1 million in cash and equivalents. Management said it expects ongoing sales and existing cash to fund settlement obligations and clinical programs without additional financing. RTTNews settlement report
• Positive Sentiment: Analyst sentiment improved following the agreement. BTIG upgraded LQDA from “neutral” to “buy” with a $70 price target, while Lifesci Capital raised its rating to “outperform” and set a $59 target. Needham maintained “buy” but lowered its target to $58.
• Positive Sentiment: Trading activity reflected strong investor interest, with call-option volume more than doubling its average level.
• Neutral Sentiment: Liquidia agreed to pay United Therapeutics a net $380.7 million, including $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to the antitrust litigation. The payments resolve the disputes but will significantly draw down cash.
• Negative Sentiment: The company will not appeal the patent ruling and is removing the PH-ILD indication from YUTREPIA’s label. It also ended promotion of Treprostinil Injection, narrowing potential revenue opportunities. Zacks settlement analysis
• Negative Sentiment: Multiple executives and insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested awards. Because the sales were planned and left executives with substantial holdings, they are a limited standalone signal, but broader insider activity remains heavily weighted toward selling.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).